Mapping of the antigenic regions of streptokinase in humans after streptokinase therapy

被引:16
作者
Torréns, I
Reyes, O
Ojalvo, AG
Seralena, A
Chinea, G
Cruz, LJ
de la Fuente, J
机构
[1] Ctr Ingn Genet & Biotecnol, Div Pharmaceut, Havana, Cuba
[2] Ctr Ingn Genet & Biotecnol, Div Phys Chem, Havana, Cuba
关键词
D O I
10.1006/bbrc.1999.0747
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Streptokinase (SK) is efficaciously used as a thrombolytic drug for the treatment of myocardial infarction. Being a bacterial protein, SK is immunogenic in humans. Therefore, resulting from SK therapy, patients become immunized and anti-SK antibody (Ab) titers rise post-treatment. High Ab titers might provoke severe immune reactions during SK therapy and neutralize SK activity, preventing effective thrombolysis. Spot synthesis combined with peptide library techniques is a useful tool for studying protein-peptide interactions on continuous cellulose membranes. Here, we report on the mapping of antigenic regions of SK using a spot-synthesized peptide library and human total sera from patients receiving SK therapy. All tested samples have high anti-SK Ab titers and most of them show significant SK neutralizing capacity. Individual variations in peptide recognition were detected. However, patients treated with SK tend, in general, to show a common regional binding pattern, including residues 1-20, 130-149, 170-189, and 390-399. This is the first study reporting the probing of a cellulose-bound set of peptides with total human sera. (C) 1999 Academic Press.
引用
收藏
页码:162 / 168
页数:7
相关论文
共 32 条
[1]  
[Anonymous], 1988, LANCET, V2, P349
[2]   THE PROLIFERATIVE RESPONSE OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS TO STREPTOKINASE - A STUDY OF PATIENTS RECEIVING A SINGLE INTRAVENOUS-INFUSION OF PURIFIED STREPTOKINASE [J].
BRUSERUD, O .
APMIS, 1990, 98 (12) :1077-1084
[3]   AT LEAST 5 ANTIGENIC EPITOPES ON THE STREPTOKINASE MOLECULE ARE RECOGNIZED BY HUMAN CD4+ TCR-ALPHA-BETA+ T-CELLS [J].
BRUSERUD, O ;
ELSAYED, S ;
PAWELEC, G .
MOLECULAR IMMUNOLOGY, 1992, 29 (09) :1097-1104
[4]  
BRUSERUD O, 1986, J CLIN LAB IMMUNOL, V20, P69
[5]   PHYSICAL AND IMMUNOLOGICAL DIFFERENCES AMONG STREPTOKINASES [J].
DILLON, HC ;
WANNAMAKER, LW .
JOURNAL OF EXPERIMENTAL MEDICINE, 1965, 121 (03) :351-+
[6]   NEUTRALIZING ANTIBODIES TO STREPTOKINASE 4 YEARS AFTER INTRAVENOUS THROMBOLYTIC THERAPY [J].
ELLIOTT, JM ;
CROSS, DB ;
CEDERHOLMWILLIAMS, SA ;
WHITE, HD .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (08) :640-645
[7]   HIGH-LEVEL EXPRESSION OF STREPTOKINASE IN ESCHERICHIA-COLI [J].
ESTRADA, MP ;
HERNANDEZ, L ;
PEREZ, A ;
RODRIGUEZ, P ;
SERRANO, R ;
RUBIERA, R ;
PEDRAZA, A ;
PADRON, G ;
ANTUCH, W ;
DELAFUENTE, J ;
HERRERA, L .
BIO-TECHNOLOGY, 1992, 10 (10) :1138-1142
[8]   SPOT-SYNTHESIS - AN EASY TECHNIQUE FOR THE POSITIONALLY ADDRESSABLE, PARALLEL CHEMICAL SYNTHESIS ON A MEMBRANE SUPPORT [J].
FRANK, R .
TETRAHEDRON, 1992, 48 (42) :9217-9232
[9]  
GERLACH D, 1979, ZBL BAKT-INT J MED M, V244, P210
[10]  
GERLACH D, 1980, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene 1 Abt Originale A, V248, P446